Head and neck involvement in atopic dermatitis significantly affects patients’ daily lives, often driving greater stigma, discomfort, and disease severity. Given this region’s impact, a post hoc analysis of the ECZTRA 1 and 2 and ECZTEND trials examined tralokinumab and found that this IL-13 inhibitor not only provided sustained reductions in head and neck EASI scores, but patients also reported better Dermatology Life Quality Index scores. Tune in to hear Dr. Raj Chovatiya dive further into the findings and their potential implications for atopic dermatitis care. Dr. Chovatiya is an Associate Professor at the Rosalind Franklin University Chicago Medical School, as well as the Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago.